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Strengths and limitations of this study
 ► This protocol describes an internet- delivered inter-
vention to explore the efficacy of attentional bias 
modification training in patients with chronic mus-
culoskeletal pain.
 ► The study will recruit a diverse sample of partici-
pants in terms of age, socioeconomic status and 
geographical region.
 ► Results will provide important information regarding 
dose effects, age effects, and participants’ experi-
ences and attitudes using the online intervention.
 ► There is limited control over the conditions under 
which training is completed.
 ► Independently verifying participant diagnosis is 
impossible.
AbStrACt
Introduction Chronic musculoskeletal pain is a complex 
medical condition that can significantly impact quality of 
life. Patients with chronic pain demonstrate attentional 
biases towards pain- related information. The therapeutic 
benefits of modifying attentional biases by implicitly 
training attention away from pain- related information 
towards neutral information have been supported in a 
small number of published studies. Limited research 
however has explored the efficacy of modifying pain- 
related biases via the internet. This protocol describes a 
randomised, double- blind, internet- delivered attentional 
bias modification intervention, aimed to evaluate the 
efficacy of the intervention on reducing pain interference. 
Secondary outcomes are pain intensity, state and 
trait anxiety, depression, pain- related fear, and sleep 
impairment. This study will also explore the effects 
of training intensity on these outcomes, along with 
participants’ perceptions about the therapy.
Methods and analysis The study is a double- blind, 
randomised controlled trial with four arms exploring 
the efficacy of online attentional bias modification 
training versus placebo training theorised to offer no 
specific therapeutic benefit. Participants with chronic 
musculoskeletal pain will be randomised to one of four 
groups: (1) 10- session attentional modification group; 
(2) 10- session placebo training group; (3) 18- session 
attentional modification group; or (4) 18- session placebo 
training group. In the attentional modification groups, the 
probe- classification version of the visual- probe task will 
be used to implicitly train attention away from threatening 
information towards neutral information. Following the 
intervention, participants will complete a short interview 
exploring their perceptions about the online training. In 
addition, a subgroup analysis for participants aged 16–24 
and 25–60 will be undertaken.
Ethics and dissemination This study has been approved 
by the University of Southampton Research Ethics 
Committee. Results will be published in peer- reviewed 
journals, academic conferences, and in lay reports for pain 
charities and patient support groups.
trial registration number NCT02232100; Pre-results.
IntroduCtIon
Chronic musculoskeletal pain (CMSK) is 
pain arising from the bones, muscles, liga-
ments, tendons and/or joints lasting for 
more than 3 months.1 Prevalence estimates 
of CMSK vary considerably, affecting between 
11.4% and 24% of the adult population2 
and between 4% and 40% of children and 
adolescents.3 Negative effects on quality of 
life are commonly reported in adult4–7 and 
paediatric8–11 CMSK populations, and theory- 
driven research12–14 has shown that patients 
with chronic pain exhibit attentional biases 
(ie, a selective attention) for salient pain- 
related words (eg, refs 15–18) and images 
(eg, refs 19 20) relative to neutral informa-
tion. Three meta- analyses have supported the 
presence of attentional biases in patients with 
chronic pain,21–23 although evidence for the 
time course of such biases is mixed. Specifi-
cally, two meta- analyses reported larger effect 
sizes when stimuli are presented for longer 
than 1000 ms,21 23 whereas a recent analysis 
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Figure 1 A graphical representation of a typical visual- probe task training trial with linguistic stimuli.
found evidence of bias for presentation times of 500–1000 
ms but not when stimuli are presented for longer than 
1000 ms.22 Despite this inconsistency, attentional biases 
are commonly shown in chronic pain, and preliminary 
research has explored the effects redirecting attention 
may have on pain and pain- related distress using atten-
tional bias modification (ABM) techniques. ABM is a 
computer- based intervention which implicitly trains 
attention away from threat- related cues towards neutral 
information, and is frequently achieved through a modi-
fied version of the visual- probe task24 (figure 1).
Two small randomised controlled trials (RCTs)25 26 and 
one pilot study27 have used the modified probe- classification 
version of the visual- probe task to assess ABM in adults 
with chronic pain. Carleton and colleagues25 found 
participants receiving ABM showed significant reduc-
tions from pre- ABM to post- ABM in anxiety sensitivity 
and fear of pain, and marginally significant reduction 
in current pain severity. No significant reductions were 
found in illness/injury sensitivity or pain anxiety. Signifi-
cantly more patients receiving ABM reported clinically 
significant change in current pain compared with those 
in the placebo group (44% vs 17%, respectively). Atten-
tional bias scores were not recorded, and therefore the 
researchers could not comment on mechanisms of action. 
Sharpe and colleagues26 found participants receiving 
ABM, compared with those in a placebo group, showed 
significant improvements in pain- related disability after 
the ABM. No significant improvements were found for 
pain, fear of pain, fear of reinjury, depression, anxiety, 
stress, anxiety sensitivity or pain self- efficacy. At 6- month 
follow- up (and after all participants had undergone eight 
sessions of cognitive behavioural therapy (CBT)) the 
ABM group, compared with the placebo group, showed 
significant improvements in disability and anxiety sensi-
tivity, and marginally significant improvements in fear of 
reinjury. No other significant effects were found, and the 
mechanism of action could not be established as ABM was 
not found to change patterns of attentional bias across 
time. Schoth and colleagues27 reported statistically and 
clinically significant change from pre- ABM to post- ABM 
in pain intensity, pain interference, anxiety and depres-
sion. Assessed via the McGill Pain Questionnaire,28 signif-
icant changes from pre- ABM to post- ABM were shown 
for total pain, affective pain and miscellaneous pain, but 
not sensory pain or evaluative pain. There was also no 
evidence that attentional biases changed across time.
One small RCT in adolescents with chronic pain 
randomised participants to either ABM, placebo training 
or waiting- list groups. No significant differences were 
found between the three groups in terms of pain, 
disability, pain catastrophising, anxiety, depression or 
objective measures of physical functioning (sit- to- stand 
task and cardio wall tasks), and no evidence was found 
that ABM changed attentional bias or attentional control 
compared with placebo and waiting- list conditions.29 
Overall, while some studies have provided support for 
the benefits of ABM in adults, the evidence in regard to 
specific outcome variables is mixed and the mechanisms 
of action have yet to be established. Given the method-
ological shortcomings and small sample sizes of previous 
studies however, further research is needed to determine 
the therapeutic benefits of ABM for patients with chronic 
pain, along with the optimal form ABM should take and 
the impact of age on outcomes and intervention engage-
ment. Considering the optimal form of ABM, a review of 
the broader cognitive bias modification (CBM) literature 
identified 12 published meta- analyses, 11 examining ABM 
specifically.30 Three out of six analyses found the number 
of sessions to be a significant moderator of CBM, and 
three out of nine analyses found the number of sessions 
to be a significant moderator of symptom outcomes. 
 o
n
 M
ay 14, 2020 at BVA. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030607 on 20 February 2020. Downloaded from 
3Liossi C, et al. BMJ Open 2020;10:e030607. doi:10.1136/bmjopen-2019-030607
Open access
Although evidence is therefore mixed, it is nevertheless 
worth exploring whether the number of sessions impacts 
the patterns of attentional bias and pain- related outcomes 
in individuals with chronic pain.
This article presents a study protocol for a randomised, 
double- blind, internet- delivered ABM intervention. The 
results of a pilot think- aloud study informing the design 
of the intervention are also presented. The aim of this 
RCT is to assess the efficacy of internet- delivered ABM in 
improving pain and pain- related distress in people aged 
16–60 with CMSK, and will report a subgroup by treatment 
effects using the two age brackets of 16–24 and 25–60. 
While only limited evidence has been found for age as 
a moderator of CBM on bias change and symptoms,30 it 
has been argued that the age of adolescence should be 
extended from 19 to 24 as the latter corresponds more 
closely to adolescent growth and popular understand-
ings of this life phase.31 Furthermore, although use of the 
internet has been growing among all age groups, there 
are nevertheless still some differences in internet use 
and activity according to age (eg, in the UK, 1% of those 
aged 16–24 do not use the internet, compared with 7% of 
those aged 45–54),32 thus warranting a separate consid-
eration of adolescent and adult participants. Overall, a 
diverse sample in terms of age, socioeconomic status and 
geographical region will be recruited, thus increasing 
generalisability of results to the CMSK population. The 
primary outcome measure is pain interference. Secondary 
outcome measures are pain intensity, state and trait 
anxiety, depression, pain- related fear and sleep impair-
ment, and engagement to and satisfaction with the online 
visual- probe training task. Dose effects will be explored 
via the inclusion of 10- session vs 18- session conditions. 
It is hypothesised that participants in the intervention 
group, relative to those in the placebo group, will report 
significant reductions in pain interference, pain intensity, 
anxiety, depression, sleep impairment and pain- related 
fear at study endline. It is also hypothesised that dose will 
significantly moderate these findings, with greater effects 
in 18 compared with 10 sessions.
MEthodS And AnAlySIS
Participants
Participants will be recruited via press announcements, 
social media and patient organisations throughout the 
UK. Inclusion criteria will be (1) aged between 16 and 
60 years old; (2) experiencing any type of CMSK (ie, 
any condition that involves pain lasting for more than 
3 months and arises from the bones, muscles and/or 
joints); (3) able to sit at a personal computer for 40 min; 
(4) normal or corrected to normal vision; (5) access to 
the internet at least twice a week; (6) access to, and famil-
iarity using, a Windows- based computer; (7) successful 
completion of primary school; and (8) living in the UK. 
Exclusion criteria will be (1) experiencing malignant 
CMSK (ie, pain due to a tumour); (2) a diagnosis of other 
forms of comorbid chronic pain (eg, chronic headache); 
and (3) a diagnosis of any psychiatric disorder, either 
currently or within the last 5 years. There are no restric-
tions placed on concomitant care, and participants are 
not required to make any changes to current treatments 
they may be receiving.
Patient and public involvement
Participant burden of the intervention and outcome 
measures were assessed using individual interviews and 
informal feedback from patients participating in two pilot 
studies.27 33 Patients will not be involved in recruitment of 
participants or conduct of the study. Results of this study 
will be disseminated to participants through presentation 
at client and community forums.
Study design and setting
The study is a double- blind RCT with four arms exploring 
the efficacy of online ABM training versus a placebo 
training condition theorised to offer no specific thera-
peutic benefits. The choice of comparator was selected 
as placebo training closely mimics ABM training, and is 
frequently used as a comparator in ABM studies (eg, refs 
25 26 34 35). The study will take place in a location of the 
participant’s choice (which we anticipate will typically be 
their home) and will be accessed via personal computer 
connected to the internet.
The study design has a 2×2×3 experimental structure, 
with multiple non- commensurate dependent variables 
measuring pain intensity and interference, emotional 
functioning, and pain- related disability. Treatment is 
a two- level factor (ABM, placebo), and the number of 
sessions is a two- level factor (10 sessions, 18 sessions), 
with measures recorded at three points in time (base-
line, endline and 6- month follow- up). Measures in the 
18- session groups (18AMG and 18PTG) will also be taken 
after session 10.
randomisation and sample size
Block randomisation of size four, performed via a 
randomisation command in the LifeGuide platform,36 
will be used to sequentially randomise eligible consecu-
tive consenting participants to one of four groups: (1) 
10- session attentional modification group (10AMG); 
(2) 10- session placebo training group (10PTG); (3) 
18- session attentional modification group (18AMG); or 
(4) 18- session placebo training group (18PTG). This 
blocked randomisation will be performed separately for 
those aged 16–24 and those aged 25–60. An allocation 
concealment mechanism will be used to ensure neither 
participants nor researchers know the study group to 
which the next participant will be assigned. This will be 
automatically performed within the LifeGuide platform 
(see The intervention section), with participants provided 
access to appropriate AMG or PTG sessions. Participants 
randomised to either 10- session condition will receive ten 
35 min online sessions across a 4- week period, while those 
randomised to either 18- session condition will receive 
eighteen 35 min online sessions across an 8- week period. 
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All online sessions will be administered twice a week on a 
separate set of days (Monday–Thursday, Tuesday–Friday). 
Participants randomised to either AMG condition will 
receive attentional training via the modified training 
version of the probe- classification visual- probe task, while 
those randomised to either PTG condition will receive 
placebo training via the standard version of the probe- 
classification visual- probe task. To maintain the overall 
quality and legitimacy of the intervention, code breaks 
(ie, unblinding) will only occur in exceptional circum-
stances. Adherence will be monitored electronically via 
LifeGuide.
Our previous lab- based, proof- of- concept ABM inter-
vention found reductions in pain intensity and pain inter-
ference from pre- ABM to post- ABM were associated with 
large effect sizes,27 although differences in methodology 
including delivery (online vs lab- based) and number 
of sessions warrant a more conservative estimate. On 
this basis, the study will recruit a minimum of 100 with 
1:1:1:1 randomisation. This study is powered primarily 
to establish treatment efficacy for the primary outcome 
variable of pain interference by considering baseline and 
measures after session 10 between those randomised to 
an attentional modification arm and those randomised 
to a placebo arm. Randomisation should ensure baseline 
comparability on measures between these two groups, 
and a difference in beneficial outcomes between these 
groups will be modelled using a linear mixed model. For 
an assumed correlation of 0.7 between baseline and end 
of session 10 measures, a total of 40 per group (ie, 20 
per randomised arm) would be needed to detect small to 
moderate standardised intervention differences (Cohen’s 
d=0.25) with at least 80% power (alpha=0.05, two- sided). 
The recruitment strategy includes a 20% oversampling to 
mitigate a loss of power from loss to follow- up.
Procedure
Interested individuals will contact the researchers on 
the details provided in study advertisements and will 
be assessed against the inclusion and exclusion criteria 
via telephone interview. If eligible, they will receive a 
copy of the participant information sheet detailing the 
requirements and procedure of the study, along with a 
link to the study website which provides further details 
on ABM and the research team. If the individual consents 
to take part, they will be required to create an online 
ABM account. During registration, participants will select 
their preferred days for training, which will be either (1) 
Monday/Thursday or (2) Tuesday/Friday.
Session 1 is the baseline session, and includes the first 
assessment visual- probe task measuring attentional biases 
prior to beginning the intervention, along with the ques-
tionnaire battery assessing the primary and secondary 
outcome measures. Randomisation will take place 
following session 1, where participants will be informed 
of the length of their training (ie, 4 or 8 weeks). Partic-
ipants randomised to either of the 10- session condi-
tions will complete four pictorial and four linguistic 
training sessions, while those randomised to either of the 
18- session conditions will complete eight pictorial and 
eight linguistic training sessions (baseline and endline 
assessment sessions comprise the remainder of the 10/18 
sessions). Participants’ attentional biases will be reas-
sessed at endline (ie, during the final session 10/18) 
using the same assessment version of the visual- probe 
task (ie, featuring the same stimuli) used at baseline and 
the same questionnaire battery. Participants randomised 
to either of the 18- session conditions will also have their 
attentional biases reassessed in session 10 after their 
training session.
Participants’ satisfaction with the online training will 
also be assessed. Six months after the last session, partici-
pants will be invited to again complete the online assess-
ment visual- probe task (same as baseline and final session 
10/18) and questionnaire battery. Within 2 weeks of the 
completion of the 6- month follow- up session, participants 
will be invited to take part in a brief telephone semistruc-
tured interview including 15 questions spread across five 
thematic sections: (1) motivation and expectations about 
the study; (2) experience of the online study: person, 
environmental and lifestyle parameters; (3) experience 
of the visual- probe task; (4) understanding of the process 
of change; and (5) the visual- probe task as a potential 
therapeutic tool in pain management. The study flow is 
presented in table 1.
To retain as many participants as possible, reminder 
emails will be sent to participants 24 hours before each 
scheduled session becomes available, and also at 13:00 
on the scheduled session date should the participant not 
have already logged into their internet- delivered ABMT 
(iABMT) account. An additional reminder email will 
be sent 1 week before their 6- month follow- up session 
is ready. Participants will also be sent encouragement 
emails informing them when they have reached specific 
milestones (ie, successfully completing 5 sessions for 
those randomised to complete 10 sessions; successfully 
completing 6 and 12 sessions for those randomised to 
18 sessions). Participants will also have the option of 
receiving an SMS (short message service) on their mobile 
phone at 09:00 on the morning of each scheduled session.
the intervention
The intervention will be hosted using LifeGuide and 
iSurvey platforms, both developed by the University of 
Southampton. LifeGuide is an open- source software 
which allows researchers to create online interventions.36 
iSurvey is a survey generation tool which allows researchers 
to create and disseminate questionnaires online. Partici-
pants will register for the intervention using LifeGuide, 
which will also host the majority of the questionnaires. 
iSurvey will be used to host the visual- probe tasks, along 
with the Engagement with the Online Training question-
naire and the Brief Pain Inventory,37 which appear at the 
end of every visual- probe task session. The flow of sessions 
is provided in figure 2, and examples of web pages are 
shown in figure 3. On loading the intervention home 
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Table 1 Schedule of enrolment, intervention and assessments
Timepoint
Study period
Enrolment Postallocation
−t1
t1
Baseline
t2
Training
t3
Evaluation
t4
Follow- up
t5
Study exit
Enrolment
Eligibility screen X
Informed consent X
Allocation X
Interventions
Attentional bias modification training X
Assessments
Demographic questionnaire X
EOT X X X X
BPI- SF X X X
HADS X X X
STAI X X X
MOS- SS X X X
FOP- III X X X
SOT X
Interview X
t1: baseline phase including standard assessment visual- probe task and questionnaires. Also includes randomisation to groups.
t2: training phase including training visual- probe tasks.
t3: evaluation phase including standard assessment visual- probe task and questionnaires. Participants randomised to 18- session conditions 
also complete evaluation phase during session 10.
t4: 6- month follow- up including standard assessment visual- probe task and questionnaires.
t5: telephone interview within 2 weeks of t4.
BPI- SF, Brief Pain Inventory- Short Form; EOT, Engagement with the Online Training questionnaire; FOP- III, Fear of Pain Questionnaire III; 
HADS, Hospital Anxiety and Depression Scale; MOS- SS, Medical Outcomes Study- Sleep Scale; SOT, Satisfaction with the Online Treatment 
questionnaire; STAI, State- Trait Anxiety Inventory.
page, the individual is provided with a brief welcome to 
the website and rationale for the intervention. A recent 
review of cognitive bias meta- analyses concluded that effect 
sizes were smaller when biases were modified remotely 
compared with laboratory- based training.30 We therefore 
decided to provide information on the rationale behind 
ABMT in order to increase motivation and reduce attri-
tion as much as possible, which also mirrors clinical prac-
tice that involves educating patients into chronic pain and 
the psychological interventions used in its management. 
Individuals are able to either create an iABMT account or 
log into their existing account. Before any session partic-
ipants are asked to indicate whether they have enough 
time and are ready to begin the session. Participants are 
only permitted to complete one session per day. Should 
a participant complete their missed session on a subse-
quently scheduled date (eg, completing their scheduled 
session from Monday on Thursday instead), all remaining 
sessions are shifted back accordingly. This process retains 
the structure of the intervention.
Guidance has been informed by research showing 
attention to be a limited capacity resource,38 39 sleepiness 
to negatively influence concentration and performance,40 
alcohol to impair speed of information processing and 
cognition,41 energy drinks to be associated with restless-
ness and nervousness,42 caffeine to improve alertness,43 
large meals to be associated with impairments in cogni-
tive functioning,44 and hunger to influence patterns of 
attention.45 46 Participants are provided with guidance 
to ensure concentration and comfort are maintained 
throughout each session: (1) allowing enough time for 
the session with no anticipated distractions; (2) adjusting 
screen brightness to match the brightness of the environ-
ment; (3) closing distracting applications such as Twitter 
and Facebook; (4) avoiding completing the session when 
tired; (5) not consuming alcohol at least 3 hours prior to 
the session; (6) caution in the use of energy drinks which 
may cause restlessness; (7) if the participant is a coffee or 
tea drinker, suggesting a cup 30 min prior to the session; 
and (8) avoiding completing the session when hungry or 
directly after a meal.
Visual-probe tasks
The flow of visual- probe sessions is illustrated in figure 2. 
In total there will be eight linguistic and eight pictorial 
probe- classification visual- probe training tasks used in 
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Figure 2 Flow of the visual- probe task sessions for the 
10- week and 18- week groups in the study. AMG, attentional 
modification group; PTG, placebo training group.
the study, each with different stimuli. A complete descrip-
tion of the stimuli including ratings of valence, arousal, 
pain intensity, written frequency and low- level features is 
provided in online supplementary material 1. To briefly 
summarise, each linguistic visual- probe task includes 
32 threatening/neutral and 16 neutral/neutral word 
pairs. Each task includes eight threatening words from 
each of the following categories: sensory pain, affective 
pain, health threat and general threat. Each pictorial 
task includes 32 threatening/neutral and 16 neutral/
neutral image pairs. Each task includes eight threatening 
images from the following categories: musculoskeletal 
pain, facial expressions of pain, health threat and general 
threat. A total of 384 trials are included in each task, with 
each stimuli pair presented four times for 500 ms and 
four times for 1250 ms. Within each exposure duration, 
each stimulus appears twice in the upper location of the 
screen and twice in the lower location.
A separate linguistic visual- probe task will be used in 
the three assessment sessions, featuring different stimuli 
to the linguistic training visual- probe tasks. The use of 
separate assessment and training stimuli is necessary to 
establish whether training effects generalise to novel 
stimuli not used in the actual training. The same assess-
ment stimuli will be used in all assessment sessions. 
The ABM training version of the visual- probe task to be 
completed by AMG groups includes three main stages 
per trial (figure 1). Following a 500 ms initial fixation 
point, a stimulus pair is presented in distinct locations 
(eg, above and below the initial fixation point) for 
either 500 or 1250 ms. The stimulus pair may be either 
words or images, although critically includes one threat- 
related and one neutral stimulus. Stimuli presentation 
times of 500 and 1250 ms are used as these are the most 
common stimuli presentation times adopted in chronic 
pain visual- probe studies (eg, refs 18 20 47) and will allow 
us to closely compare our results with those of previous 
research. Immediately following their presentation, the 
stimuli disappear and a probe appears (either ‘p’ or ‘q’) 
in the location of the neutral stimulus. Participants use 
corresponding keys on their keyboard to indicate the 
probe letter as quickly and as accurately as possible. In 
the standard version of this paradigm completed by PTG 
groups and used in the assessment sessions, the probe 
replaces the neutral and threat- related stimulus an equal 
number of times. The probe- classification version of the 
visual- prove task is argued to encourage a more even 
monitoring of the display than the probe- position version 
(ie, which requires participants to indicate the location 
of a dot, either left/right or up/down), as for the latter 
participants can adopt biased monitoring strategies 
favouring one particular region over the other.48 As any 
such biases in monitoring may affect training, we will use 
the probe- classification version of the visual- probe task.
outcome measures
The primary outcome measure of pain interference will 
be assessed by the Brief Pain Inventory- Short Form.37 Pain 
interference will be scored as the mean of seven interfer-
ence items (ie, general activity, walking, work, mood, enjoy-
ment of life, relations with others and sleep). Following 
guidance in the Brief Pain Inventory User Guide49 and 
also Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (IMMPACT) recommenda-
tions for assessing pain in clinical trials,50 we will include 
individual assessments of ‘worst’, ‘least’, ‘average’ and 
‘now’ (ie, current) pain intensity as secondary outcome 
measures. Additional secondary outcome measures of 
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Figure 3 Examples of LifeGuide web pages included in the internet- delivered attentional bias modification training 
intervention.
state and trait anxiety will be assessed by the State Trait 
Anxiety Inventory,51 depression by the Hospital Anxiety 
and Depression Scale,52 pain- related fear by the Fear of 
Pain Questionnaire III,53 sleeping impairment by the 
Medical Outcomes Study- Sleep Scale,54 and engagement 
to and satisfaction with the online visual- probe training 
task by the Satisfaction with the Online Training ques-
tionnaire (SOT)55 and the Engagement with the Online 
Training questionnaire (EOT). A demographic question-
naire developed by the researchers will be used at base-
line to collect information on participants’ age, gender, 
ethnicity, socioeconomic status, place of residence and 
pain characteristics. Aside from the SOT and EOT, ques-
tionnaires in the 10- session groups (10AMG and 10PTG) 
will be administered to participants at baseline, after 
10 sessions and at 6- month follow- up. In the 18- session 
groups (18AMG and 18PTG), questionnaires will be 
administered to participants at baseline, after 10 sessions, 
after 18 sessions and at 6- month follow- up. At endline for 
each participant, we will also assess whether the partic-
ipant and researchers became aware at any point prior 
to endline which group they had been allocated to. Full 
details on each outcome measure are provided in online 
supplementary material 2.
think-aloud study
A qualitative think- aloud study33 including a short semi-
structured interview was conducted following the devel-
opment of the initial version of the intervention with the 
aim to understand participants’ first impressions and atti-
tudes towards the intervention, and to collate feedback 
that could be used to make improvements. Details and 
outcomes of this study are provided in online supplemen-
tary material 3.
Analyses of the rCt data
Quantitative analyses
A full and detailed statistical analysis plan will be written 
prior to trial closure. In brief, the data analysis will 
be performed on an intention- to- treat (ITT) basis to 
provide an unbiased estimate of the treatment effect.56 
Per- protocol analyses will also be performed (comprising 
those correctly randomised, without protocol violations, 
and providing complete data on the primary outcome 
measure). Sweetman and Doig57 have identified five types 
of protocol violations, namely violations in (1) enrolment 
(ie, failure to correctly apply eligibility criteria resulting 
in the enrolment of an inappropriate participant); (2) 
randomisation (ie, violation of intended randomisation 
sequence); (3) study intervention (ie, dosing, timing or 
delivery errors attributable to members of the research 
team); (4) patient compliance (ie, participants failing 
to comply with the trial protocol or other requirements 
of participation in the trial, such as skipping scheduled 
appointments or sessions); and (5) data collection (ie, a 
failure by the research team to comply with prespecific 
trial guidelines for data collection and/or outcome eval-
uation due to avoidable reasons). Any such violations will 
be clearly reported.
Analyses undertaken will include the following:
1. The primary analysis on pain interference will use the 
initial 2×2×2 structure comprising stage (baseline, 10 
weeks), randomised treatment (attentional bias mod-
ification training (ABMT), placebo) and randomised 
number of sessions (10, 18). This comparison will be 
extended to compare 10AMG and 10PTG after 10 
sessions, and to compare 18AMG and 18PTG after 10 
sessions.
2. An analysis of pain interference will use the 2×2×3 
structure comprising randomised treatment (ABMT, 
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placebo), randomised number of sessions (10, 18) and 
stage (baseline, endline, follow- up).
3. An assessment of change in pain interference, both 
within and between groups, for 18AMG and 18PTG, 
between the end of session 10 and endline.
4. The four randomised arms compared against one an-
other on pain interference at each of baseline, after 
session 10, endline and follow- up.
5. An age (16–24, 25–60) subgroup analysis using an age 
subgroup by treatment effect interaction. These analy-
ses will be an extension of (1), (2) and (3) to incorpo-
rate age as a subgroup factor.
The same analyses would apply to the secondary 
outcome measures. The data will be represented descrip-
tively and graphically by arm, and by treatment and age, 
and standardised effect sizes reported.
Linear mixed model with random intercepts will be 
used to analyse the data with, as appropriate, treatment 
(ABMT, placebo), number of sessions (10, 18) and assess-
ment stage as fixed factors. This approach avoids listwise 
deletion which would apply in a repeated measures anal-
ysis of variance approach. The linear mixed modelling 
approach uses all of the available data and adheres to 
ITT. As a secondary analysis we will used multiple imputa-
tion chained equations to impute outcome data58 59 and 
use these imputed data sets in the linear mixed model. 
Pairwise comparisons will follow the same procedure. An 
assessment of the sensitivity of findings to missing data 
mechanisms will be undertaken.60 61 Specifically, we will 
use the strategy discussed by Morris and colleagues61 
whereby multiply imputed values are altered by a 
randomised group- dependent value prior to analysis. We 
will run this sensitivity analysis over a factorial arrange-
ment of group- dependent values constraining any altered 
imputed values to be in the valid response range. The 
instance of the group- dependent values both being equal 
to zero will correspond to multiple imputation under 
missing at random (MAR), and non- zero values would 
reflect deviations away from this assumption. The analysis 
plan would apply to the primary outcome measure and 
secondary outcome measures.
Similar to previous studies,25 27 the Reliable Change 
Index62 will be used to assess primary and secondary 
outcome measures for clinically significant changes. 
Here, a clinically significant result is a post- treatment 
score falling outside 2 SD of the mean population of 
interest (in this study, 2 SD outside pretreatment means). 
In contrast to tests of statistical significance comparing 
group means, tests of clinical significance explore effects 
of treatment on the individual.63
For visual- probe data, and as per previous research,19 27 
practice and incorrect trials will be removed prior to anal-
yses. Box and whisker plots for overall data will be used to 
reveal overall outliers, which will be removed. Following 
this, mean response times will be computed for each 
participant, with any response >3 SD from their individual 
mean also removed as outliers. This process ensures 
extremely quick or slow responses do not unduly bias 
the results, which are typically removed when cleaning 
and screening visual- probe data in pain- related research 
(eg, refs 18 64–67). An attentional bias index will then be 
computed for each stimulus and presentation time condi-
tion using the following equation: (TuPl−TlPl)+(TlPu−
TuPu)/2. Here T is the threatening stimulus, P is the 
probe, u is the upper position and l is the lower position. 
The attention capturing quality of threatening stimuli is 
measured by subtracting the mean probe classification 
time for congruent trials from the mean probe classifica-
tion time of incongruent trials.21
Split- half reliability will be computed via a bootstrap 
procedure, by randomly splitting the total number of 
trials in two halves, such that each half has the same 
number of congruent and incongruent trials. Attentional 
bias scores will be computed for each half and the correla-
tion between them calculated across participants. This 
procedure will be repeated 100 times, and an average 
split- half correlation computed.
Qualitative analyses
Qualitative analysis will be used to detail participants’ expe-
riences completing the iABMT intervention. Specifically, 
thematic analysis using inductive coding will be used to 
identify themes present in the data obtained from the semi-
structured interviews and the two open- ended questions 
included in the SOT questionnaire. Guidelines provided 
by Braun and Clarke68 will be followed. Following verbatim 
transcription of all interviews, initial codes will be gener-
ated. Potential themes and subthemes will then be iden-
tified from the initial coding, which subsequently will be 
reviewed and refined. The validity of the themes in relation 
to the data set will also be considered. Each theme and 
subtheme will then be named and defined, and a thematic 
map of the data finalised. Examples from the data will be 
illustrated for each theme and subtheme in the final report.
Ethics and dissemination
The study protocol was registered with  ClinicalTrials. gov, 
with a planned start date of September 2020 and a planned 
end date of September 2022. All data will remain confi-
dential and stored on password- protected systems and 
databases. LifeGuide and iSurvey servers both use HTTPS 
(hypertext transfer protocol secure) connections for secu-
rity purposes. All data will be anonymised prior to dissemi-
nation, and personally identifiable information not known 
to anyone other than the researchers. Participants may 
withdraw from the intervention at any point by contacting 
the researchers via email or telephone, or by simply opting 
not to log into their iABMT account for their scheduled 
sessions. Participants are also encouraged to contact the 
researchers should they experience any distress or discom-
fort completing the intervention. As per university policy, 
any adverse events, harms or complaints arising from partic-
ipation in the intervention will be reported to the Univer-
sity of Southampton Research Governance Office. Findings 
will be published in the most relevant, high- impact, peer- 
reviewed journals and presented at relevant conferences. 
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Lay reports will be written for interested pain charities and 
patient support groups.
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